Rebate sharing, exclusion lists, and application of QALY measures are all approaches that PBMs are likely to ramp up in 2020, predicts Todd Edgar. Todd examines the impact of new formulary guidelines and makes some predictions on other trends likely in the coming year.
With the Trump Administration’s recent withdrawal of their proposal to modify the rebate safe harbor, what do manufacturers need to know in preparing for the future? Todd Edgar reviews the history of the proposal and offers some advice.
With the release of the HHS safe harbor proposal, more information is available than when only the title was public. Indeed, over the past few weeks, many articles have been published with detailed summaries of the proposal—yet, many questions remain. For All Access, Todd Edgar breaks down some of the most granular issues to consider and asks the question: How prepared is the market for a change of this magnitude?
The current administration is considering removing the safe harbor protection used to prevent drug rebates from being considered a kickback. While the details are still developing, such a move would likely have significant impacts on PBMs, manufacturers, and patients. Todd Edgar explores the possible ramifications.
Todd Edgar, Senior Vice President, Payer Access Solutions, outlines multistakeholder perspectives of quality-based care and how these can be in conflict. Todd discusses potential solutions to bring views into alignment, with the goal of improving quality-driven care within the system.
